ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 134 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,754,089 | -28.9% | 187,143 | 0.0% | 7.23% | +33.5% |
| Q2 2023 | $5,279,304 | +3.3% | 187,143 | -37.0% | 5.42% | +29.2% |
| Q1 2023 | $5,110,860 | -14.6% | 297,143 | 0.0% | 4.20% | +32.4% |
| Q4 2022 | $5,984,460 | -68.1% | 297,143 | -15.7% | 3.17% | -84.7% |
| Q2 2021 | $18,751,000 | -99.9% | 352,459 | -2.8% | 20.74% | +14.5% |
| Q1 2021 | $15,727,096,000 | +83439.2% | 362,459 | 0.0% | 18.11% | -20.1% |
| Q4 2020 | $18,826,000 | +30.1% | 362,459 | -18.1% | 22.65% | +16.1% |
| Q3 2020 | $14,472,000 | -31.9% | 442,714 | +0.0% | 19.50% | -4.1% |
| Q2 2020 | $21,259,000 | – | 442,713 | – | 20.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |